Please login to the form below

Not currently logged in
Email:
Password:

Saxenda

This page shows the latest Saxenda news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk’s semaglutide obesity trial hits the mark

Novo Nordisk’s semaglutide obesity trial hits the mark

1 drug Saxenda (liraglutide 3mg) as an active control.

Latest news

More from news
Approximately 7 fully matching, plus 9 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Media

Four Health Media creates world class integrated media solutions with global reach, deep insight, innovative methods and a highly personal...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics